文献速递认知障碍与痴呆帕金森病与运动障碍

DLB中脑脊液α-突触核蛋白种子扩增检测与阿尔茨海默病生物标志物:表现与进展

CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression.
PubMed 文献 · Neurology · 2025-11-17

本研究基于DLB联盟多中心前瞻性队列,分析99例临床诊断DLB患者的脑脊液αSyn-SAA及AD生物标志物。68%为αSyn-SAA阳性,其基线认知及运动功能更差且嗅减退更常见。αSyn-SAA阳性者运动功能年下降更快,合并AD共病理者认知与功能下降额外加重。

要点

  • αSyn-SAA阳性DLB患者基线MoCA更低、MDS-UPDRS III更高、嗅减退更常见。
  • αSyn-SAA阳性者帕金森综合征年进展显著快于阴性者。
  • αSyn-SAA阳性合并AD共病理者认知与功能年下降进一步加重。

核心结论

  • 在临床诊断DLB队列中,αSyn-SAA阳性与更快的运动功能下降相关。
  • AD共病理常见,并额外增加认知和功能下降风险。

研究设计与样本

  • DLB联盟多中心前瞻性纵向队列的横断面分析,纳入99例有脑脊液αSyn-SAA和AD生物标志物数据的参与者。
  • 基线评估1年内采集脑脊液,检测αSyn-SAA及Aβ42/40、p-tau181、t-tau。
  • 采用线性混合效应模型评估不同脑脊液特征组的纵向认知和运动下降。

主要发现

  • 68%(67/99)为αSyn-SAA阳性;αSyn-SAA阳性者基线MoCA为19.0±5.8 vs 21.6±4.7(p=0.03)。
  • αSyn-SAA阳性者基线MDS-UPDRS III为32.3±15.8 vs 22.1±14.4(p=0.003),嗅减退比例87%(46/53)vs 37%(10/27)(p<0.0001)。
  • αSyn-SAA阳性者MDS-UPDRS III年进展3.70分/年(95%CI 2.60-4.80)vs 阴性者0.47分/年(95%CI -0.25至1.19)(p<0.0001)。
  • αSyn-SAA阳性者中39%(26/67)为AD-,52%(35/67)为AD+;AD+者MoCA年下降-3.24分/年(95%CI -4.12至-2.36)vs AD-者-1.19分/年(95%CI -1.72至-0.65)(p<0.0001)。
  • αSyn-SAA+AD+者MDS-UPDRS I年增加2.72分/年(95%CI 1.70-3.73)vs AD-者1.21分/年(95%CI 0.48-1.94)(p=0.03);II年增加4.60分/年(95%CI 3.40-5.80)vs 1.93分/年(95%CI 1.19-2.66)(p<0.001)。

关键数值与推荐

  • AD-定义为Aβ42/40、p-tau181和t-tau均正常。
  • AD+定义为Aβ42/40异常,±p-tau181,±t-tau。
  • 其他非AD定义为Aβ42/40正常但p-tau181或t-tau升高。

临床怎么用

  • 脑脊液αSyn-SAA和AD生物标志物可用于DLB患者预后分层,识别运动或认知下降更快的个体。
  • αSyn-SAA阳性合并AD共病理提示认知和功能下降风险更高,可能有助于临床试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: α-Synuclein (αSyn) seed amplification assays (SAAs) accurately detect αSyn pathology in dementia with Lewy bodies (DLB). Alzheimer disease (AD) copathology occurs in ∼70% of patients with DLB at autopsy. The association of different αSyn-SAA and AD biomarker profiles with clinical outcomes in DLB can aid prognostication and inform clinical trial design. METHODS: This is a cross-sectional study of participants in the DLB Consortium (DLBC) study. The DLBC is a multicentered prospective longitudinal cohort study with participants recruited at tertiary care centers in the United States. CSF samples obtained within 1 year of baseline assessments were analyzed using αSyn-SAA and for β-amyloid (Aβ) 42/40, phosphorylated tau (p-tau) 181, and total tau (t-tau). Comparisons of baseline prevalence and degree of core DLB features, cognitive impairment, and hyposmia in participants with different CSF profiles were performed (AD-: normal Aβ42/40, p-tau181, and t-tau. AD+: Aβ42/40 abnormal, ±p-tau181, ±t-tau. Other non-AD: normal Aβ42/40 but elevated p-tau181 or t-tau levels). Longitudinal cognitive and motor declines were assessed in participants with different CSF profiles using linear mixed-effects models. RESULTS: Ninety-nine participants had CSF αSyn-SAA and AD biomarkers available for analysis (mean age 69.8 ± 6.6, 15% female); 68% (67/99) were αSyn-SAA+. αSyn-SAA+ participants had lower baseline Montreal Cognitive Assessment (MoCA) scores (19.0 ± 5.8 vs 21.6 ± 4.7, p = 0.03) and worse motor parkinsonism (Movement Disorder Society Unified Parkinson's Disease Rating Scale [MDS-UPDRS] part-III 32.3 ± 15.8 vs 22.1 ± 14.4, p = 0.003) and were more likely to be hyposmic (87% [46/53] vs 37% [10/27], p < 0.0001). αSyn-SAA+ participants had more progressive parkinsonism than αSyn-SAA- participants (MDS-UPDRS part-III: 3.70 points per year [95% CI 2.60-4.80] vs 0.47 points per year [95% CI -0.25 to 1.19], p < 0.0001). Of αSyn-SAA+ participants, 39% (26/67) were AD- and 52% (35/67) were AD+. αSyn-SAA+AD+ participants had greater declines in MoCA scores than αSyn-SAA+AD- participants (-3.24 points per year [95% CI -4.12 to -2.36] vs -1.19 points per year [95% CI -1.72 to -0.65], p < 0.0001). MDS-UPDRS part-I and part-II subscores increased more in αSyn-SAA+AD+ participants than in αSyn-SAA+AD- participants (2.72 points per year [95% CI 1.70-3.73] vs 1.21 points per year [95% CI 0.48-1.94], p = 0.03 and 4.60 points per year [95% CI 3.40-5.80] vs 1.93 points per year [95% CI 1.19-2.66], p < 0.001, respectively). DISCUSSION: In this well-characterized cohort of participants with clinically diagnosed DLB, αSyn-SAA positivity is associated with greater motor decline. AD copathology is common and confers additional risk of cognitive and functional decline.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Coughlin DG, Jain L, Khrestian M, et al. CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression. Neurology. 2025. PMID: 41248454. doi:10.1212/WNL.0000000000214346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。